Evidence map›Paper›PMID 40894158›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Electronic health records to test multimorbidity influences to plasma biomarker interpretation for Alzheimer's disease.

Katheryn A Q Cousins, Rory Boyle, Colleen Morse, Anurag Verma, Christopher A Brown, Kyra S O'Brien, Marina Serper, Nadia Dehghani, Penn Medicine BioBank, Corey T McMillan and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Katheryn A Q CousinsDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.ORCID 0000-0003-1879-2766
Rory BoyleDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.ORCID 0000-0003-0787-6892
Colleen MorsePenn Medicine BioBank, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.
Anurag VermaPenn Medicine BioBank, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.
Christopher A BrownDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.ORCID 0000-0003-2057-3976
Kyra S O'BrienDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.
Marina SerperDepartment of Medicine in Gastroenterology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.
Nadia DehghaniDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.
Penn Medicine BioBank
Corey T McMillanDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.ORCID 0000-0002-7581-6405
Edward B LeeDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.
Leslie M ShawDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.
David A WolkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania; 3600 Spruce Street, Philadelphia, PA 19104.

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Technology Identification and Training CoreP30AG073105 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DEMIRIS, GEORGE, KARLAWISH, JASON H · 2021 to 2025
$21.2M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8M
Pathology-guided biofluid biomarker strategies for classification and progression of frontotemporal lobar degeneration (FTLD)R01AG087258 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Katheryn Alexandra Quilico Cousins · 2024 to 2026
$2.4M
NCATS NIH HHS UL1 TR001878NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG073105NIA NIH HHS R01 AG087258
6 · The paper itself

Abstract

Objective: Plasma biomarkers of Alzheimer's disease (AD) pathology are frequently tested in specialized research settings, limiting generalizability of findings. Using electronic health records and banked plasma, we evaluated plasma biomarkers - phosphorylated tau 217 (p-tau Methods: Participants (n=617; 44% Black/African American; 41% female) were selected from the University of Pennsylvania Medicine BioBank with plasma assayed using Fujirebio Lumipulse. International Classification of Diseases (ICD) Ninth and Tenth Revision codes determined AD dementia (ADD; n=43), mild-cognitive impairment (MCI; n=140), unspecified/non-AD cognitive impairment (CI; n=106), and cognitively normal cases (n=328), and other medical histories. APOE ε4, body mass index (BMI), metrics of kidney function ( Results: Plasma p-tau Interpretation: In this real-world dataset, we identified effects of multimorbidities on plasma biomarkers, especially kidney function. The p-tau

Indexed as

Alzheimer’s diseaseAβ42/Aβ40eGFRkidney dysfunctionplasma biomarkersp-tau217p-tau217/Aβ42

Identifiers

PMID40894158
PMCPMC12393648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.